We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





LumiraDx Demonstrates Use of LumiraDx Platform in Infectious Disease Testing at ECCMID 2022

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: LumiraDx exhibited at ECCMID live for the first time (Photo courtesy of LumiraDx)
Image: LumiraDx exhibited at ECCMID live for the first time (Photo courtesy of LumiraDx)

LumiraDx (London, UK) exhibited at ECCMID live for the first time where it demonstrated the use of its LumiraDx platform in infectious disease testing. The last two editions of ECCMID were only accessible through the website, as the pandemic made impossible to exhibit on live. This year, the 32nd edition of the European Congress of Clinical Microbiology and Infectious Diseases took place in a hybrid event held in person and online.

At ECCMID 2022, LumiraDx demonstrated its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders, at point of care and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions for use on the LumiraDx Platform, including its LumiraDx SARS-CoV-2 Ag Test, LumiraDx SARS-CoV-2 Ag Pool Test and LumiraDx SARS-CoV-2 Ab Test.

Related Links:
LumiraDx 

New
Gold Supplier
Quantitative Immunoassay Analyzer
FIA8000
New
Gold Supplier
Body Fluid Application
CellaVision Body Fluid Application
New
Platinum Supplier
Animal Tissues Genomic DNA Extraction Kit
Animal Tissues Genomic DNA Extraction Kit - T093H
New
COL-R Assay
CHROMagar COL-APSE

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.